BioCryst Pharmaceuticals | BCRX - DEBITO





DEBITO Cambiamento Data
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Chugai Pharma JPY 14.11B 1.93B 2022-12
Daiichi Sankyo JPY 300.48B 99.34B 2026-03
DBV Technologies USD 6.1M 2.49M 2026-03
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 22.17B 2.76B 2026-03
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
Incyte USD 38.27M 1.16M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novavax USD 233.31M 4.23M 2024-09
PTC Therapeutics USD 286.94M 2.42B 2026-03
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.98B 8.9M 2026-06